{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:06:45Z","timestamp":1792112805453,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTUQQR-Dec22\/100005"],"award-info":[{"award-number":["CTUQQR-Dec22\/100005"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8162\/A29083"],"award-info":[{"award-number":["C8162\/A29083"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eclinm.2026.103862","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:27:58Z","timestamp":1775096878000},"page":"103862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluating the basis for use of advanced stage as a surrogate endpoint for cancer mortality in screening trials: a simulation study of meta-correlation and an alternative framework"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-8744","authenticated-orcid":false,"given":"Peter D.","family":"Sasieni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Brentnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.eclinm.2026.103862_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194818","article-title":"Cell-Free DNA-Based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial","volume":"14","author":"Neal","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103862_bib2","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1470-2045(24)00015-9","article-title":"Considerations for using potential surrogate endpoints in cancer screening trials","volume":"25","author":"Webb","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/09691413241256744","article-title":"Strong association between reduction of late-stage cancers and reduction of cancer-specific mortality in meta-regression of randomized screening trials across multiple cancer types","volume":"31","author":"Dai","year":"2024","journal-title":"J Med Screen"},{"issue":"22","key":"10.1016\/j.eclinm.2026.103862_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/jama.2024.5814","article-title":"Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis","volume":"331","author":"Feng","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103862_bib5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1158\/1055-9965.EPI-25-0201","article-title":"Late-stage outcomes as surrogates for mortality in cancer screening trials: a systematic review and meta-analysis","volume":"34","author":"Rebolj","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103862_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/10543406.2015.1094811","article-title":"Statistical approaches for evaluating surrogate outcomes in clinical trials: a systematic review","volume":"26","author":"Ensor","year":"2016","journal-title":"J Biopharm Stat"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pst.2219","article-title":"Informed decision-making: statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments","volume":"21","author":"Weir","year":"2022","journal-title":"Pharm Stat"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103862_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2307\/2529884","article-title":"The efficiency of the proportions test and the Logrank test for censored survival data","volume":"38","author":"Cuzick","year":"1982","journal-title":"Biometrics"},{"issue":"17","key":"10.1016\/j.eclinm.2026.103862_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-Specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.eclinm.2026.103862_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"issue":"10290","key":"10.1016\/j.eclinm.2026.103862_bib13","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/biom.12879","article-title":"Estimation of the optimal surrogate based on a randomized trial","volume":"74","author":"Price","year":"2018","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103862_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/EDE.0000000000000078","article-title":"Causal models and learning from data: integrating causal modeling and statistical estimation","volume":"25","author":"Petersen","year":"2014","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103862_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/biostatistics\/kxaf018","article-title":"A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development","volume":"26","author":"Gilbert","year":"2025","journal-title":"Biostatistics"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103862_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103862_bib18","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.csda.2010.01.016","article-title":"Simplified modeling strategies for surrogate validation with multivariate failure-time data","volume":"54","author":"Corti\u00f1as Abrahantes","year":"2010","journal-title":"Comput Stat Data Anal"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103862_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/biostatistics\/kxs003","article-title":"A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials","volume":"13","author":"Dai","year":"2012","journal-title":"Biostatistics"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103862_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1740774508091677","article-title":"Alternative methods to evaluate trial level surrogacy","volume":"5","author":"Abrahantes","year":"2008","journal-title":"Clin Trials"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:05:20Z","timestamp":1778904320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"alternative-id":["S2589537026001094"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103862","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the basis for use of advanced stage as a surrogate endpoint for cancer mortality in screening trials: a simulation study of meta-correlation and an alternative framework","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103862"}}